Loading...

Phio Pharmaceuticals

BST:44R2
Snowflake Description

Adequate balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
44R2
BST
$7M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Phio Pharmaceuticals Corp., a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The last earnings update was 105 days ago. More info.


Add to Portfolio Compare Print
44R2 Share Price and Events
7 Day Returns
0%
BST:44R2
-1.3%
DE Biotechs
1.4%
DE Market
1 Year Returns
-
BST:44R2
-8%
DE Biotechs
-10.7%
DE Market
44R2 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Phio Pharmaceuticals (44R2) 0% 0% 0.8% - - -
DE Biotechs -1.3% -7% -6% -8% 75.1% 4.5%
DE Market 1.4% 1.5% 1.1% -10.7% 9.9% 7.9%
1 Year Return vs Industry and Market
  • No trading data on 44R2.
  • No trading data on 44R2.
Price Volatility
44R2
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Phio Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Phio Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is €0.26.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Phio Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Phio Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BST:44R2 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in USD $-2.28
NasdaqCM:PHIO Share Price ** NasdaqCM (2018-11-30) in USD $0.38
Europe Biotechs Industry PE Ratio Median Figure of 25 Publicly-Listed Biotechs Companies 23.02x
Germany Market PE Ratio Median Figure of 420 Publicly-Listed Companies 18.32x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Phio Pharmaceuticals.

BST:44R2 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:PHIO Share Price ÷ EPS (both in USD)

= 0.38 ÷ -2.28

-0.17x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Phio Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Phio Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Phio Pharmaceuticals's expected growth come at a high price?
Raw Data
BST:44R2 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.17x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
-23%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.77x
Germany Market PEG Ratio Median Figure of 277 Publicly-Listed Companies 1.41x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Phio Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Phio Pharmaceuticals's assets?
Raw Data
BST:44R2 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in USD $0.39
NasdaqCM:PHIO Share Price * NasdaqCM (2018-11-30) in USD $0.38
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 2.63x
Germany Market PB Ratio Median Figure of 565 Publicly-Listed Companies 1.76x
BST:44R2 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:PHIO Share Price ÷ Book Value per Share (both in USD)

= 0.38 ÷ 0.39

0.97x

* Primary Listing of Phio Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Phio Pharmaceuticals is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Phio Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Phio Pharmaceuticals has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Phio Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-23%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Phio Pharmaceuticals expected to grow at an attractive rate?
  • Unable to compare Phio Pharmaceuticals's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Phio Pharmaceuticals's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Phio Pharmaceuticals's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
BST:44R2 Future Growth Rates Data Sources
Data Point Source Value (per year)
BST:44R2 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts -23%
BST:44R2 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 37.5%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 29.7%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 25.4%
Germany Market Earnings Growth Rate Market Cap Weighted Average 10%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BST:44R2 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BST:44R2 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 0 -12 1
2019-12-31 0 -9 1
2018-12-31 0 -8 1
BST:44R2 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-09-30 0 -8 -8
2018-06-30 0 -8 -9
2018-03-31 0 -9 -9
2017-12-31 0 -10 -12
2017-09-30 0 -9 -15
2017-06-30 0 -8 -15
2017-03-31 0 -8 -14
2016-12-31 0 -8 -11
2016-09-30 0 -8 -9
2016-06-30 0 -8 -10
2016-03-31 0 -8 -10
2015-12-31 0 -7 -10

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Phio Pharmaceuticals is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Phio Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BST:44R2 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Phio Pharmaceuticals Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:44R2 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31 -0.42 -0.36 -0.48 2.00
2019-12-31 -0.35 -0.33 -0.36 2.00
2018-12-31 -1.81 -1.81 -1.81 1.00
BST:44R2 Past Financials Data
Date (Data in USD Millions) EPS *
2018-09-30 -2.28
2018-06-30 -3.04
2018-03-31 -3.90
2017-12-31 -5.52
2017-09-30 -8.05
2017-06-30 -10.27
2017-03-31 -13.94
2016-12-31 -16.41
2016-09-30 -14.16
2016-06-30 -14.62
2016-03-31 -15.86
2015-12-31 -20.99

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Phio Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Phio Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Phio Pharmaceuticals has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Phio Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Phio Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Phio Pharmaceuticals does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Phio Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Phio Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Phio Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Phio Pharmaceuticals Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:44R2 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 0.15 -7.64 3.19
2018-06-30 0.10 -8.62 3.46
2018-03-31 0.04 -9.23 3.79
2017-12-31 0.02 -12.45 4.01
2017-09-30 0.00 -14.86 4.24
2017-06-30 0.00 -14.60 4.01
2017-03-31 0.01 -14.30 3.79
2016-12-31 0.02 -11.07 3.62
2016-09-30 0.02 -9.27 3.49
2016-06-30 0.02 -9.56 3.50
2016-03-31 0.01 -9.53 3.42
2015-12-31 0.03 -10.43 3.35
2015-09-30 0.05 -10.58 3.21
2015-06-30 0.06 -10.99 3.20
2015-03-31 0.08 -12.02 3.25
2014-12-31 0.07 -12.93 3.22
2014-09-30 0.09 -13.89 3.57
2014-06-30 0.16 -14.49 3.74
2014-03-31 0.38 -15.63 3.86
2013-12-31 0.40 -29.54 3.70
2013-09-30 0.41 -28.44 3.20
2013-06-30 0.38 -27.86 2.81
2013-03-31 0.15 -41.71 2.55
2012-12-31 0.10 -25.70 2.62
2012-09-30 0.06 -25.52 2.95 1.55
2012-06-30 -24.64 3.45 2.68
2012-03-31 -8.30 3.78 4.47

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Phio Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Phio Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Phio Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Phio Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Phio Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Phio Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Phio Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Phio Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Phio Pharmaceuticals has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Phio Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Phio Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Phio Pharmaceuticals Company Filings, last reported 4 months ago.

BST:44R2 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 1.75 0.00 3.24
2018-06-30 3.27 0.00 5.32
2018-03-31 0.57 0.00 2.61
2017-12-31 1.83 0.00 3.58
2017-09-30 3.43 0.00 5.42
2017-06-30 5.94 0.00 7.70
2017-03-31 8.25 0.00 10.21
2016-12-31 10.86 0.00 12.91
2016-09-30 3.04 0.00 4.38
2016-06-30 4.97 0.00 5.83
2016-03-31 6.95 0.00 7.69
2015-12-31 8.89 0.00 10.62
2015-09-30 11.03 0.00 12.04
2015-06-30 13.13 0.00 13.99
2015-03-31 5.61 0.00 6.58
2014-12-31 7.86 0.00 8.50
2014-09-30 9.75 0.00 10.13
2014-06-30 11.50 0.00 11.91
2014-03-31 11.07 0.00 12.01
2013-12-31 12.86 0.00 14.39
2013-09-30 14.87 0.00 15.85
2013-06-30 16.49 0.00 17.59
2013-03-31 18.01 0.00 19.64
2012-12-31 3.89 0.01 5.13
2012-09-30 5.30 0.01 6.28
2012-06-30 6.65 0.02 7.58
2012-03-31 -1.78 1.02 0.36
  • Phio Pharmaceuticals has no debt.
  • Phio Pharmaceuticals had no debt 5 years ago.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Phio Pharmaceuticals has less than a year of cash runway based on current free cash flow.
  • Phio Pharmaceuticals has less than a year of cash runway if free cash flow continues to grow at historical rates of 4.3% each year.
X
Financial health checks
We assess Phio Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Phio Pharmaceuticals has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Phio Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Phio Pharmaceuticals dividends.
If you bought €2,000 of Phio Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Phio Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Phio Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BST:44R2 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 332 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BST:44R2 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2020-12-31
2019-12-31
2018-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Phio Pharmaceuticals has not reported any payouts.
  • Unable to verify if Phio Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Phio Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Phio Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Phio Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Phio Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Phio Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Phio Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Geert Cauwenbergh
COMPENSATION $422,527
AGE 64
TENURE AS CEO 6.8 years
CEO Bio

Dr. Geert Cauwenbergh, Ph.D., Dr., Med.Sc., has been the Chief Executive Officer of RXi Pharmaceuticals Corporation since April 27, 2012. Dr. Cauwenbergh served as the President of RXi Pharmaceuticals Corporation from April 27, 2012 to November 14, 2018 and also served as its Acting Chief Financial Officer. Dr. Cauwenbergh served as Scientific Advisor of Skin Care, Dermatology, Wound Care, OTC, Infectious Diseases, Women’s Health at Q BioMed Inc. until April 2018. Dr. Cauwenbergh serves as Senior Advisor of Wombat Capital. Dr. Cauwenberghhas been the Head of International Advisory Board at Skinvisible Inc. since November 2008. He has been the Official Trade Advisor to the Belgian Government for Health Care in the USA since 2004. He served as Business Advisor of Edge Therapeutics, Inc., since June 2010. He has more than 20 years experience in international research, clinical drug development and new product commercialization for both specialty pharmaceuticals and anti-infectives at both pharmaceutical and biotechnology companies, including Johnson & Johnson (J&J) and the Janssen Research Foundation in Belgium. Dr. Cauwenbergh served as the Chief Executive Officer of RHEI Pharmaceuticals Inc., from August 1, 2008 to June 2011 and also served as its Chairman. He served as Managing Director of the Center for Medical Innovation, a government subsidized center for translational medicine for the Belgian Region of Flanders. Prior to joining RHEI Pharmaceuticals in February 2008, he was a founder and Chief Executive Officer of Phases123, LLC. He founded Barrier Therapeutics Inc. in September 2001 and served as its Executive Chairman from September 2001 to June 2006, Chief Executive Officer from September 2001 to March 31, 2008 and also served as its President. He founded Aramis LLC in May 2009. Prior to founding Barrier, Dr. Cauwenbergh held a number of ascending senior management positions at Johnson & Johnson, where he was employed for 23 years. He served at Johnson & Johnson (in both the U.S. and Europe) Consumer and Personal Care Products Companies from 2000 to 2002, where he served as Vice President of Technology, where he created technology platforms based on intellectual property and know-how owned by it and developed a business proposition around these platforms as the basis for new companies or new businesses within or outside it. From 1994 to 2000, Dr. Cauwenbergh served as Global Vice President of Research & Development at Johnson & Johnson Consumer Companies Worldwide. He served as Vice President, Research and Development for Johnson & Johnson's Skin Research Center and was responsible for the worldwide research and development of all skin care products for the Johnson & Johnson consumer companies. Dr. Cauwenbergh served as Vice President, Product Development and a Member of the Management Board of U.S. J&J Consumer Company since 1994. In his career, he served positions in sales and national and international marketing and he was responsible for the successful global introduction of Nizoral (ketoconazole). His R&D activities had also involved him in the fields of psoriasis, acne, wound healing, atopic dermatitis, protozoal infections and HIV. He served as an Executive Chairman at ECI Biotech. He serves as the Chairman of Expressive Constructs, Inc. He served as the Chairman of BioNJ Inc. Dr. Cauwenbergh served as the Chairman of Bio New Jersey from 2009 to 2010. He has been a Director of RXi Pharmaceuticals Corporation since April 2012. Dr. Cauwenbergh serves as a Member of the Board of Trustees at Bio New Jersey. He has been a Director of Cutanea Life Sciences Inc. since July 9, 2010. He has been a Director of Moberg Pharma AB (publ) (alternate name: Moberg Derma AB) since April 23, 2012. He serves as a Director of RHEI. He served as an Independent Director of Ablynx NV until April 25, 2013. He served as a Member of the Board of Intercept Inc. (US), from 2003 to 2005. He served as a Director of RealSource Residential, Inc. (Upstream Biosciences, Inc.) from March 25, 2008 to December 14, 2009. He served as a Director of Euroscreen S.A since July 2008. He served as an Independent Non Executive Director at Phosphagenics Limited since February 28, 2014 until May 2017. He served as a Director of Midatech Pharma US Inc. (DARA BioSciences, Inc.) from June 14, 2008 to April 4, 2009. He served as a Member of the Business Development Council at J&J. Dr. Cauwenbergh served in the R&D organization of the Janssen Research Foundation since 1982, where he served in positions of increasing global responsibility as an International Director of Clinical R&D, Dermatology and Infectious Diseases and oversaw development of drugs such as Sporanox, Nizoral Shampoo, Terazol and topical Sufrexa. He served as the Director of Corporate Skin Care Council of J&J, co-ordinating all skin care activities in the different operating groups of Corporation. From 2004 to 2006, he served as a Member on the Board of Trustees of the New Jersey Center of Life Sciences. He has authored over 100 publications and co-authored several books. In 2004, he was inducted into the New Jersey High Tech Hall of Fame. Dr. Cauwenbergh received his PhD in Medical Sciences from the Catholic University of Leuven, Faculty of Medicine, Belgium where he also completed his Masters and undergraduate work. He holds Bachelor's Degree and Master's Degree from Katholieke Universiteit Leuven. He is Fluent in English, French, German and Dutch.

CEO Compensation
  • Geert's compensation has been consistent with company performance over the past year.
  • Geert's remuneration is higher than average for companies of similar size in Germany.
Management Team

Geert Cauwenbergh

TITLE
CEO & Director
COMPENSATION
$423K
AGE
64
TENURE
6.8 yrs

Gerrit Dispersyn

TITLE
President & COO
COMPENSATION
$231K
AGE
43
TENURE
0.3 yrs

Caitlin Kontulis

TITLE
Senior Director of Finance & Secretary
AGE
32
Board of Directors Tenure

Average tenure and age of the Phio Pharmaceuticals board of directors in years:

6.2
Average Tenure
66
Average Age
  • The tenure for the Phio Pharmaceuticals board of directors is about average.
Board of Directors

Bob Bitterman

TITLE
Chairman of the Board
COMPENSATION
$36K
AGE
67
TENURE
7.1 yrs

Geert Cauwenbergh

TITLE
CEO & Director
COMPENSATION
$423K
AGE
64
TENURE
6.8 yrs

Keith Brownlie

TITLE
Director
COMPENSATION
$36K
AGE
66
TENURE
6.7 yrs

Curt Lockshin

TITLE
Director
COMPENSATION
$31K
AGE
58
TENURE
5.8 yrs

Pamela Pavco

TITLE
Member of Scientific Advisory Board
COMPENSATION
$515K
AGE
62
TENURE
1.8 yrs

Jeannette Graf

TITLE
Member of Scientific Advisory Board
TENURE
6.6 yrs

V. Young

TITLE
Member of Scientific Advisory Board
TENURE
6.6 yrs

H. Dorman

TITLE
Director
COMPENSATION
$26K
AGE
82
TENURE
5.8 yrs

Peter Campochiaro

TITLE
Member of Scientific Advisory Board
TENURE
4.6 yrs

Rolf Kiessling

TITLE
Member of Scientific Advisory Board
AGE
70
TENURE
2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Phio Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Phio Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Map
Description

Phio Pharmaceuticals Corp., a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company’s lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye. The company also develops Samcyprone, a topical formulation of the small molecule diphenylcyclopropenone that is in a Phase IIa clinical trial for the clearance of common warts; RXI-231, an sd-rxRNA compound targeting tyrosinase, as a cosmetic ingredient that may enhance the appearance of uneven skin tone and pigmentation; and RXI-185, an sd-rxRNA compound targeting collagenase, as a cosmetic ingredient that may improve the appearance of wrinkles or skin laxity. In addition, it develops RXI-109, a Phase I/II clinical trial that reduces the progression of retinal scarring. The company has collaborations with the Center for Cancer Immune Therapy; Gustave Roussy; Medigene AG; PCI Biotech; and Karolinska Institutet. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

Details
Name: Phio Pharmaceuticals Corp.
44R2
Exchange: BST
Founded: 2011
$6,074,120
18,164,356
Website: http://https://phiopharma.com/
Address: Phio Pharmaceuticals Corp.
257 Simarano Drive,
Suite 101,
Marlborough,
Massachusetts, 01752,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM PHIO Common Stock Nasdaq Capital Market US USD 10. May 2012
DB 44R2 Common Stock Deutsche Boerse AG DE EUR 10. May 2012
BST 44R2 Common Stock Boerse-Stuttgart DE EUR 10. May 2012
Number of employees
Current staff
Staff numbers
15
Phio Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/02/27 22:38
End of day share price update: 2018/11/30 00:00
Last estimates confirmation: 2018/11/19
Last earnings filing: 2018/11/14
Last earnings reported: 2018/09/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.